Timeline — 2025 through May 2026
| Date | Event | Implication for compounded GLP-1 telehealth |
|---|---|---|
| Feb 2025 | FDA declares semaglutide shortage resolved. | Removes one of the legal bases for 503A and 503B compounding of “essentially a copy” products. |
| Mid-2025 | Tirzepatide shortage stabilizes. | Same legal-basis erosion for tirzepatide. |
| Sep 2025 | FDA initiates broader crackdown on DTC compounded GLP-1 advertising; first wave of warning letters. | Signals enforcement priority. Compliant operators begin tightening marketing language. |
| Feb 5, 2026 | TrumpRx launches with FDA-approved tirzepatide injections at $299–$449/mo and semaglutide injections at $199–$349/mo. | Creates a lower-cost FDA-approved pathway; compresses the compounded-vs-branded price gap. |
| Feb 6, 2026 | FDA announces intent to restrict GLP-1 APIs used in non-FDA-approved compounded products; names Hims & Hers in the announcement. | Signals direct enforcement on named operator. Marketing-language exposure is highlighted as primary concern. |
| Feb 9, 2026 | Novo Nordisk sues Hims & Hers for patent infringement on oral semaglutide formulation. | Litigation track in parallel with FDA enforcement. |
| Mar 3, 2026 | FDA issues warning letters to 30 telehealth companies for misleading compounded GLP-1 marketing. | Second major enforcement wave. Sameness claims, generic-equivalent language, and obscured-source branding all cited as violations. 15-day response window. |
| Mar 9, 2026 | Hims & Hers announces partnership with Novo Nordisk: will market branded Wegovy and Ozempic, ceases compounded GLP-1 marketing except where medically necessary. | Most-visible compounded GLP-1 marketer exits the category. Patent suit dismissed. |
| Apr 30, 2026 | FDA Federal Register notice (docket 2026-08552) proposes excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. | If finalized as written, ends 503B outsourcing-facility compounding from bulk API. 503A patient-specific compounding pathway unaffected. Public comment closes June 29, 2026. |
| May 21, 2026 | WeighLossCompare first cross-site consensus analyses published (semaglutide / tirzepatide “most affordable” pages). | The consensus pages are constructed against this regulatory snapshot. Material change to any of the above triggers an out-of-cycle update. |
What survives the enforcement window
The Tier A audited publications converge on a small set of structural compliance criteria that distinguish operators likely to survive the 2026 enforcement window from operators likely to be subject to further action. The audit treats these criteria as the threshold for inclusion in any “cheapest” consensus analysis: a provider that fails one or more of these criteria is excluded from the modal calculation regardless of its advertised price.
- Compounding pathway disclosure. Operator names its 503A and/or 503B compounding pharmacies on the pricing or product page, not on a buried legal sub-page. Operators with “our partner pharmacy” or equivalent generic language are higher-risk.
- No “sameness” marketing. Operator does not describe its compounded product as “the same as Wegovy/Ozempic/Mounjaro/Zepbound” or as a “generic version” of the branded product. Compounded-vs-FDA-approved distinction is stated affirmatively.
- Individualized medical-necessity documentation. Operator’s prescribing physicians document patient-specific medical necessity in the prescription record, the structural basis for 503A pathway eligibility.
- FDA-non-named formulation. Operator’s active ingredient is the form the FDA has not named in salt-form enforcement actions: semaglutide base, not semaglutide sodium or semaglutide acetate; tirzepatide active acid form.
- LegitScript certification or equivalent third-party verification. Operator carries a current LegitScript Healthcare Merchant Certification or equivalent independent third-party verification that screens advertising-and-marketing compliance posture on an ongoing basis.
The cross-site consensus #1 on both most affordable compounded semaglutide and most affordable compounded tirzepatide — NexLife — satisfies all five of the above structural criteria. The Tier A audited publications cite this combination as the reason NexLife’s position is robust to the 2026 enforcement window, not merely a function of advertised price.
What the audit is watching
- June 29, 2026 close of the 503B Bulks comment period, and the FDA’s subsequent final determination. A final exclusion of semaglutide and tirzepatide from the 503B Bulks List would force a structural change in the operator set; consensus pages will be re-audited within 30 days of any final FDA determination.
- State-level board actions. Several state boards of pharmacy have initiated investigations in parallel with the federal enforcement track. The audit maintains a state-status grid; the cross-site consensus pages note state-of-residence eligibility variation where relevant.
- Further FDA warning letters. The 2025–2026 letter cadence suggests additional waves are likely. Operators newly named in a warning letter are removed from the “lowest-priced compliant” consensus set within 14 days, regardless of price competitiveness.
- Branded-product price changes. TrumpRx price adjustments and Eli Lilly / Novo Nordisk direct-to-consumer initiatives compress the compounded-vs-branded price gap. The consensus pages annotate the gap and update when material change is observed.
Primary source citations: FDA press release “FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s” (March 3, 2026); Federal Register docket 2026-08552 (April 30, 2026); FDA Commissioner Marty Makary public statements (February–April 2026). The audit does not summarize FDA documents beyond what is materially relevant to the cross-site consensus pages; readers seeking the full text are directed to the primary sources at fda.gov and regulations.gov.